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ABSTRACT The transforming growth factor ,Bs (TGF-
,Bs) are a group of multifunctional growth factors which
inhibit cell cycle progression in many cell types. The TGF-,p-
induced cell cycle arrest has been partially attributed to the
regulatory effects of TGF-j8 on both the levels and the
activities of the G1 cyclins and their kinase partners. The
activities ofthese kinases are negatively regulated by a number
of small proteins, p21 (WAFi, Cipl), p27KiPl, p16, and
p15INK4B, that physically associate with cyclins, cyclin-
dependent kinases, or cyclin-Cdk complexes. p21 has been
previously shown to be transcriptionally induced by DNA
damage through p53 as a mediator. We demonstrate that
TGF-13 also causes a rapid transcriptional induction of p21,
suggesting that p21 can respond to both intracellular and extra-
cellular signals for cell cycle arrest. In contrast to DNA
damage, however, induction of p21 by TGF-j3 is not dependent
on wild-type p53. The cell line studied in these experiments,
HaCaT, contains two mutant alleles of p53, which are unable
to activate transcription from the p21 promoter when over-
expressed. In addition, TGF-j3 and p53 act through distinct
elements in the p21 promoter. Taken together, these findings
suggest that TGF-j8 can induce p21 through a p53-
independent pathway. Previous findings have implicated
p27KiP' and p15INK2B as effectors mediating the TGF-f3 growth
inhibitory effect. These results demonstrate that a single
extracellular antiproliferative signal, TGF-j8, can act through
multiple signaling pathways to elicit a growth arrest response.
The transforming growth factor 13s (TGF-/3s), a group of
protein hormones which regulate many cellular functions,
inhibit cell proliferation by causing growth arrest in the G1
phase of the cell cycle (1-4). Progression through G1 is
dependent on the sequential formation, activation, and sub-
sequent inactivation of the G1 cyclin-Cdk complexes, primarily
cyclin D-Cdk4 and cyclin E-Cdk2 complexes (5, 6). The
TGF-f3-induced G1 cell cycle arrest has been partially attrib-
uted to the regulatory effects of TGF-,B on both the levels and
activities of these G1 cyclins and Cdks (7-9). Recently, a family
of low molecular weight cyclin-dependent kinase inhibitors
(CdkIs) have been shown to play essential roles in arresting cell
cycle progression. These Cdkls, which include p21 (WAF1,
Cipl), p27KiPl, p16, and pl5INK4B, physically associate with
their target cyclin-Cdk complexes to inhibit their activities
(10-19).
p21 was first identified as a component of the quaternary
complex composed of cyclin D, Cdk4, and proliferating cell
nuclear antigen (PCNA) (20). Subsequent cloning and char-
acterization indicated that p21 is under the transcriptional
control of p53 (11), is transcriptionally induced by y-irradia-
tion (10, 21), acts as an inhibitor of multiple cyclin-Cdk
complexes (11, 13, 16), and controls DNA replication by
interaction with PCNA (22). Because of these characteristics,
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p21 is thought to be an effector for p53-mediated suppression
of cell proliferation in response to DNA damage (10, 11, 16,
21-23). In comparison to p21, p27 has been shown to be
induced only by extracellular signals for growth arrest. p27 was
initially identified as an inhibitor of cyclin E-Cdk2 complex
activity in TGF-13 treated or contact inhibited mink lung
epithelial cells (14). p27 has since been cloned and shown to
cause a G1 cell cycle arrest when overexpressed (24, 25). The
mechanism by which p27 is activated by TGF-,B is still unre-
solved.
On the basis of these observations, it has been postulated
that these two inhibitor molecules may mediate growth arrest
signals from two distinct sources: p21 responds to intracellular
signals initiated by DNA damage with p53 as the mediator,
whereas p27 responds to extracellular signals, such as TGF-,B
and cell contact (23). The fact that p21 is a potent inhibitor of
cell cycle progression prompted us to test if it can also be
regulated by TGF-f3 and consequently serve as an effector in
TGF-f3-mediated growth inhibition.
EXPERIMENTAL PROCEDURES
Cell Culture. HaCaT was a gift of P. Boukamp and N.
Fusenig (26). SW480 cells were obtained from the American
Type Culture Collection. Both types of cells were maintained
in a-MEM (GIBCO/BRL) containing 10% fetal bovine serum.
Northern Blot Analysis. Approximately 5 x 106 HaCaT cells
in 15-cm culture dishes were incubated in the presence or
absence of 100 pM TGF-,B1 for various times. Total RNA was
isolated and Northern blot analysis was performed, using a
2-kb full-length human p21 cDNA or rat glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) probe as previously de-
scribed (27). Fold induction of p21 mRNA was calculated by
normalizing the levels of p21 mRNA to the level of GAPDH
mRNA and comparing the amount of p21 mRNA to the
amount of p21 in untreated HaCaT cells.
Immunoprecipitation and Western Blot Analysis. Approx-
imately 1 X 106 HaCaT cells in 10-cm culture dishes were
incubated in the presence or absence of 100 pM TGF-f31 for
20 hr. During the final 4 hr of treatment, cells were incubated
in methionine-free medium to which 0.25 mCi (1 mCi = 37
MBq) of [35S]methionine per ml (Tran35S label, ICN) had been
added. Cells were then lysed in 1 ml of a Nonidet P-40 lysis
buffer (50 mM Tris HCl, pH 7.4/150mM NaCl/0.5% Nonidet
P-40) in the presence of proteinase inhibitors. Immunopre-
cipitations were done with 0.5 ,ug of polyclonal antibodies to
p21 (27), Cdk2 (17), and cyclin Dl (17) from equal amounts
of lysate as previously described (17). For samples in which a
competing p21 peptide antigen was used, anti-p21 antibody
was preincubated with 0.5 ,ug of a peptide containing the 15
amino-terminal amino acids of p21. For Western blot analysis,
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equal protein amounts of total cell lysate or immunoprecipi-
tates from equal amounts of cell lysate were resolved on an
SDS/15% polyacrylamide gel. Proteins were transferred onto
Immobilon transfer paper (Millipore) and probed with a
polyclonal anti-p21 antibody (PharMingen) as previously de-
scribed (21). The blots were developed by using the ECL (en-
hanced chemiluminescence) detection method (Amersham).
Cdk2 Histone Hi Kinase Assay. HaCaT cells were treated
as described for Cdk2 immunoprecipitation assays. Immuno-
precipitated Cdk2 was washed once with kinase reaction buffer
(50mM Tris HCl, pH 7.5/10mM MgCl2, 1 mM dithiothreitol).
Kinase assays were then performed in 50 ,l of the kinase
buffer, S ,ug of histone Hi (Boehringer Mannheim), and 10
ACi of [,y-32P]ATP at 30°C for 30 min as previously described
(7). Samples were resolved on a 15% polyacrylamide gel and
autoradiography was performed.
Growth Inhibition Assay. HaCaT cells were plated into
12-well plates at a density of 20,000 cells per well and treated
with 100 pM TGF-,B1 for various times. The cells were labeled
for the last 2 hr with 4 ,uCi of [3H]thymidine, fixed in 10%
trichloroacetic acid, and lysed in 0.2 M NaOH. [3H]thymidine
incorporation into the DNA was measured with a scintilation
counter.
Creation of p21 Promoter Deletion Constructs. The p21
promoter construct, WWP-luc, was a gift of B. Vogelstein (11).
The 2.4-kb HindIII fragment of WWP-luc, containing the p21
promoter region, was inserted into a luciferase reporter con-
struct, pGL2-basic (Promega), to create p21P. The 5' end of
the promoter was digested with the restriction enzymes Bgl II
and Kpn I and a progressive deletion of the p21 promoter was
performed by using the exonuclease III system, Erase-a-Base
(Promega). p21PA1.1 was determined to have undergone a
deletion of approximately 1.1 kb from the 5' end of the p21
promoter. p21P-SmaA1 was created by Sma I digestion and
religation of p21P.
Creation of a HaCaT cDNA Library and Isolation of the
HaCaT Mutant Alleles of p53. Total RNA was isolated by the
method of RNAzol (Biotecx Laboratories, Houston) from
HaCaT cells, and poly(A)-containing RNA was further iso-
lated by using a protocol provided by Promega. The construc-
tion, packaging, and screening of the HaCaTA-ZAP II cDNA
library were done according to the protocols of Stratagene.
The probe used in the screening was a 1.2-kb p53 cDNA. A
total of 20 positive clones were isolated from initial screening.
Four of these clones were found to represent distinct cDNA
















with differences in the 5' and 3' nontranslated region. Further
sequence analysis indicated that two of the clones contain a
mutation at codon 282 resulting in an arginine-to-tryptophan
substitution, and two clones contain a mutation at codon 179
with a histidine-to-tyrosine substitution. These results are
consistent with the previously reported mutations in the
HaCaT p53 alleles (29). All four cDNAs were cloned in the
expression vector pCMV5 for transfection assays.
Luciferase Assays. HaCaT cells were plated into six-well
plates at a density of 200,000 cells per well and grown
overnight. Cells were transfected with 6 gg of p21P, p21PA1.1,
or p21P-SmaA1, using DEAE-dextran as described (28). Six
hours after transfection cells were incubated in the presence or
absence of 100 pM TGF-f31 for 20 hr. Cells were lysed and the
amount of luciferase activity in the lysates was assayed by
integrating total light emission over 30 sec, using a Berthold
luminometer (28).
SW480 cells were plated similarly and cotransfected with 2
jig of reporter construct (p21P, p21PA1.1, or p21P-SmaA1)
and 0.5 ,ug of the wild-type p53 construct, pll-4 (30), 0.5 ,ug
of the HaCaT mutant p53 constructs, or 0.5 ,ug of the vector,
pCMV5; 0.5 ,ug of a ,B-galactosidase reporter construct was
included to normalize luciferase activity to transfection effi-
ciency. Transfections were performed by using the standard
Ca2(PO4)3 DNA precipitation method. Luciferase activity was
assayed 24 hr after transfection. Fold induction was calculated
by normalizing luciferase activity to 13-galactosidase activity
and comparing the luciferase activity in SW480 cells cotrans-
fected with either the wild-type or the mutant p53 constructs
with those cotransfected with the vector.
RESULTS
p21 mRNA and Protein Levels Increase upon TGF-f3 Treat-
ment of HaCaT Cells. Previous studies have shown that p21 is
transcriptionally activated by DNA damage, and an accumu-
lation of p21 mRNA ultimately leads to inhibition of the
activity of the G1 cyclin-Cdk complexes (11, 13, 16). To investi-
gate whether TGF-3 also affects the steady-state level of p21
mRNA, we studied the effects ofTGF-f3 on p21 in HaCaT (26),
a cell line of spontaneously immortalized human keratinocytes
which can be growth arrested by TGF-j31 in G1 (8). An
asynchronous population of HaCaT cells was treated with
TGF-,1 for 20 hr, and Northern blot analysis was performed.
TGF-f3 treatment resulted in an approximately 6- to 7-fold






















FIG. 1. Induction of p21 expression by TGF-3. (A) Effect ofTGF-f3 on the steady-state level of p21 mRNA. Northern blot analysis was performed
on RNA samples derived from TGF-f3-treated and -untreated cells. Equal loading was confirmed by ethidium bromide staining and hybridization
with a rat GAPDH mRNA probe. (B) Time course of p21 mRNA induction by TGF-,B. RNA samples were isolated from asynchronously growing
HaCaT cells at different times after treatment with TGF-,B1 and Northern blot analysis for p21 was performed. [3H]Thymidine incorporation was
measured on similarly treated cells; incorporation is relative to cells not treated with TGF-f3. (C) Transcriptional activation of the p21 promoter
by TGF-,B. Cells were transiently transfected with 6 ,ug ofWWP-Luc (11) and TGF-f3-induced luciferase activity was measured. Error bars represent
the average deviation of two separate measurements of two transfections in a single experiment.
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FIG. 2. Effect of TGF-f3 on the level of p21 protein. (A) TGF-,3
treatment increases the level of p21 protein. Asynchronously growing
HaCaT cells were incubated in presence or absence of TGF-131 for 20
hr, metabolically labeled with [35S]methionine, and immunoprecipi-
tated with antisera against human p21 in the presence or absence of
a competing p21 peptide antigen. Positions of 18- and 29-kDa markers
are indicated on the left. (B) Association of p21 with cyclin Dl upon
TGF-,3 treatment. HaCaT cells were synchronized to a quiescent state
by growth to confluency followed by 3 days of serum starvation in 0.2%
fetal bovine serum (FBS) in a-MEM. Cells were then split to 10% FBS
in a-MEM in the presence or absence of 100 pM TGF-,31. After 16 hr,
cells were metabolically labeled and immunoprecipitations were per-
formed with antisera specific to human cyclin Dl. Asynchronously
growing human diploid fibroblast W138 cells were analyzed in parallel
as a control (16). Similar results were obtained when asynchronously
growing HaCaT cells were used in the analysis. (C) Western blot
analysis of p21 protein levels on whole cell lysate and immunopre-
cipitations with antibodies to cyclin Dl and Cdk2 in TGF-13-untreated
and -treated HaCaT cells. (D) Histone Hi kinase activity of Cdk2
immunoprecipitates in TGF-,B-treated and -untreated HaCaT cells.
with untreated cells (Fig. 1A). p21 mRNA induction is rapid;
an increase in p21 mRNA was observed as early as 1 hr after
TGF-f treatment. The steady-state level of p21 mRNA con-
tinues to increase for several hours after TGF-,B addition and
reaches a plateau 8 hr later. The time course of p21 induction
parallels an inhibition of DNA synthesis in these cells upon
TGF-13 treatment as assayed by [3H]thymidine incorporation
(Fig. 1B).
To determine the mechanism by which TGF-,B induces the
accumulation of p21 mRNA, a plasmid construct harboring a
luciferase reporter gene under the transcriptional control of
the p21 promoter, WWP-Luc (11), was transfected into Ha-
CaT, and TGF-f-induced luciferase activity was measured.
TGF-f3 treatment of transfected cells resulted in a 4- to 5-fold
increase in luciferase activity (Fig. 1C). This result suggests
that TGF-f3-induced accumulation of p21 mRNA is in part a
consequence of transcriptional activation of the p21 gene.
We next examined if the observed transcriptional activation
of the p21 gene leads to an increase in the p21 protein level.
Immunoprecipitation of 35S metabolically labeled HaCaT cell
lysates with a polyclonal anti-p21 antibody revealed a signifi-
cant increase of p21 protein in cells treated with TGF-13 (Fig.
2A). Western blot analysis of p21 further confirmed this
increase in p21 protein upon TGF-,B treatment (Fig. 2C).
HaCaT cell lysates were next immunoprecipitated with a
variety of cyclin and Cdk antibodies to determine if the
TGF-13-induced increase in p21 protein leads to association of
p21 with its cyclin or Cdk targets. When [35S]methionine
metabolically labeled cell lysates were immunoprecipitated
with antibodies against a number of GI cyclins and Cdks, we
found that the level of p21 associated with cyclin Dl was
significantly increased in TGF-,3-treated cells in comparison
with untreated cells (Fig. 2B). On Western blot analysis for
p21, we also observed that TGF-f3 treatment results in an
increased association of p21 with both cyclin Dl and Cdk2
(Fig. 2C).
Since p21 has been previously shown to inhibit the kinase
activity of cyclin E-Cdk2 complexes, we analyzed the activity
of Cdk-2 upon TGF-f3 treatment. Cdk2 was immunoprecipi-
tated from both TGF-f3-treated and -untreated HaCaT cells,
and the activity of Cdk2 was assayed by measuring its ability to
phosphorylate an exogenous substrate, histone Hi. As shown
in Fig. 2D, TGF-f3 treatment resulted in a marked decrease in
Cdk2 kinase activity. This observed decrease in Cdk2 kinase
activity on TGF-,B treatment is consistent with the possibility
that it is a result of p21 association. It is also possible, however,
that this decrease in Cdk2 kinase activity is a result of the
activation of multiple CdkIs, including p21, p15, and p27, which
may all be capable of inhibiting Cdk2 activity (14, 19, 24, 25).
TGF-8 Induces p21 Through a p53-Independent Mecha-
nism. Similar to the observed TGF-f3 induction of p21, DNA
damage has been previously shown to cause a transcriptional
activation of p21. This induction is dependent on the presence
of a functional p53 (10, 21). To determine the role of p53 in
TGF-f3-mediated induction of p21, we studied the regions of
the p21 promoter responsible for its activation both by p53 and
by TGF-j3. As described in Experimental Procedures, a series of
5' deletion constructs of the p21 promoter were created. One
of these constructs (p21PA1.1) has undergone a 1.1-kb dele-
tion from the 5' region of the 2.4-kb p21 promoter, removing
the previously described consensus p53-responsive element
(11). A second deletion construct of the p21 promoter (p21P-
SmaAl1) contains only 60 bp ofDNA proximal to the previously
defined transcription start site (11).
HaCaT cells were transfected with these two reporter
constructs and TGF-,3-induced luciferase activity was mea-
sured. As shown in Fig. 3, the full-length p21 promoter
construct (p21P) and the 1.1-kb deletion construct (p21PA1.1)
showed identical extents of induction by TGF-,. This is in
contrast to the minimal promoter construct (p21P-SmaA1)
c
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FIG. 3. TGF-,B-inducible and p53-inducible elements in the p21 promoter are distinct. Transcriptional activation of the p21 promoter constructs
by TGF-f3 was determined by transiently transfecting HaCaT cells with 6 ,ug of WWP-Luc and measuring TGF-3-induced luciferase activity. Fold
induction was determined by comparing luciferase activity of TGF-,B-treated cells to that of untreated cells and was averaged among four separate
transfections in two different experiments. Activation of the p21 promoter constructs by p53 was determined by cotransfecting 2 ,ug of the promoter
constructs with 0.5 jig of p11-4 into SW480 cells and measuring luciferase activity. Fold induction was determined by comparing luciferase activity
in cells transfected with pll-4 to cells transfected with vector and averaging among four separate transfections in two different experiments.
which showed no induction by TGF-, (Fig. 3). We next assayed
the ability of these constructs to be induced by overexpression
of p53 in SW480 cells, a colon carcinoma cell line which has
been used to assess the activity of p53 (11). The full-length p21
promoter construct (p21P) was activated 7-fold over vector
control by overexpression of the wild-type p53. This is in
contrast to the two deletion constructs, which are not induced
by p53 overexpression (Fig. 3). From these results, we con-
cluded that the sites responsible for p53-mediated induction of
the 2.4-kb p21 promoter region are in the 1.1-kb region deleted
in p21PA1.1. The sites responsible for activation by TGF-f3,
however, are in the 3' 1.3-kb half of this promoter. Thus, the
regions of the promoter responsible for the induction by
TGF-f3 and p53 overexpression are distinct.
To further investigate the role of p53 in TGF-f3-mediated
induction of p21, we examined the functional nature of the
HaCaT endogenous p53 alleles. It has been reported that
HaCaT possesses two mutant alleles of p53, each containing a
single amino acid substitution (29). Both of these residues
could play important structural and functional roles (31), as
supported by the observation that they are mutated at a
significantly increased frequency in various types of tumor cells
(32, 33). To confirm that HaCaT expresses these mutant alleles
of p53, we created a HaCaT cDNA library and isolated both
mutant alleles of p53. By sequence analysis, these mutant p53
cDNAs were determined to represent individual clones which
contain the entire coding region for p53, as well as the two
specific point mutations, as previously described (29). To study
the functional consequences of these mutations, the cDNAs
were inserted into the expression vector pCMV5 and their
function was studied by cotransfection with the full-length p21
promoter construct in SW480 cells (11). As shown in Fig. 4,
wild-type p53 activated the p21 promoter by approximately
6-fold. In contrast, the two HaCaT mutant alleles of p53 failed
to activate the p21 promoter when overexpressed. Identical
results were obtained when an additional independent clone
for each mutant allele of p53 was used. These results suggest
that both alleles of p53 expressed in HaCaT cells are incapable
of transcriptionally activating the p21 promoter and support a
hypothesis that TGF-,3 activates the p21 promoter through a
p53-independent pathway.
DISCUSSION
It has been proposed that TGF-f3 causes a G1 cell cycle arrest
by regulating the activity of the G1 cyclin-Cdk complexes,
primarily cyclin D-Cdk4 and cyclin E-Cdk2 (7-9). We present
a possible mechanism through which TGF-,B may act to inhibit
the activities of these complexes. Our results demonstrate that
TGF-,B causes a rapid and significant induction of a cyclin-Cdk
inhibitor, p2l. This induction of p2l leads to its increased
association with at least two of its G1 targets, cyclin Dl and
Cdk2. It has been previously reported that p21 can bind to and
inhibit the kinase activity of both cyclin D-Cdk4 and cyclin
E-Cdk2 complexes (11, 13, 16, 18). Thus, the observed in-
crease in p21 level and its association with cyclin D1 and Cdk2
upon TGF-f3 treatment may be sufficient to inhibit the activ-
ities of these complexes. In support of this, a decrease in the
kinase activity of Cdk2 was also observed upon TGF-3 treat-
ment. Our results also demonstrate that the induction of p21
by TGF-, is concurrent with an inhibition of cell entry into S
phase. These results, taken together with previous findings
which implicate a similar involvement of p21 in DNA damage-
induced cell cycle arrest (10, 21), suggest that the induction of
p21 by TGF-13 may play a causative role in TGF-f3-mediated
inhibition of cell growth. These results also support a model in
which an individual Cdk inhibitor, p21, can serve as an effector
for diverse signals for cell cycle arrest, including intracellular
signals such as DNA damage and extracellular signals, such as
TGF-,B.
Previous work in mink lung epithelial cells has suggested
that p27 may serve as an effector in TGF-,B-mediated growth
inhibition (14, 24). It has been proposed that p27 is released
from cyclin D1-Cdk4 complexes upon TGF-/3 treatment and
subsequently associates with cyclin E-Cdk2 complexes to block
its kinase activity (14, 23, 24). Recently, p1SINK4B, another
inhibitor of the Gl cyclin-Cdk complexes, was found to be
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FIG. 4. Functional analysis of the HaCaT alleles of p53. Activation
of the full-length p21 promoter construct by p53 and by the two mutant
HaCaT alleles of p53 (His-179 -± Tyr and Arg-282 -- Trp) was
determined by cotransfecting 2 ,ug of the promoter constructs with 0.5
,ug of the p53 expression constructs into SW480 and measuring
luciferase activity. Results shown are of a representative experiment.
Error bars represent the average deviation of two measurements of
two separate transfections in a single experiment.
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in HaCaT cells (19). These results, together with our findings,
clearly support the idea that TGF-f3 may affect cell cycle
progression by inducing the activities of multiple CdkIs
through at least two different mechanisms. These inhibitors,
p21, p27, and p15, may serve both unique and overlapping
functions in inhibiting the activities or the activation of the G1
cyclin-Cdk complexes in response to TGF-f3. Specific inhibi-
tors may function preferentially to inhibit specific complexes.
Thus, the combined action of multiple inhibitors may be
necessary to completely inhibit the progression of cells into S
phase. Conversely, each inhibitor alone may be sufficient to
block the activity of G, cyclin-Cdk complexes and cause cell
cycle arrest. In this case, simultaneous induction of several
inhibitors by TGF-f3 may have evolved to serve as a functional
safeguard to ensure a proper response to a growth-inhibitory
signal. It is also possible that different individual inhibitors act
in different cell types or under different growth conditions to
mediate the growth-inhibitory effects of TGF-13.
The TGF-,B-mediated induction of p21 in HaCaT cells
reported here is not a unique phenomenon. We have recently
observed a similar induction of p21 expression by TGF-, in
MCF-7 breast epithelial carcinoma cells stably expressing the
TGF-,B type II receptor (ref. 34; M.B.D. and X.-F.W., unpub-
lished results). In addition, the TGF-,B-mediated p21 induction
has been reported in TGF-13-responsive ovarian cancer cell
lines (35).
In assessing the potential role of p53 in TGF-f-mediated
induction of p21, we studied the specific regions in the p21
promoter which are responsible for the transcriptional activa-
tion of p21 by TGF-13 and by p53. We have found that the
promoter elements necessary for the induction of p21 by
TGF-, and by p53 are physically unlinked. We have since
determined that the TGF-/3-responsive element is harbored in
a 30-bp DNA fragment near the transcription initiation site of
the p21 promoter (M.B.D. and X.-F.W., unpublished results).
These results suggest that TGF-P3 transcriptionally activates
p21 through a p53-independent mechanism. This tentative
conclusion is further supported by our confirmation that both
alleles of p53 in HaCaT cells encode mutant p53 proteins
which are incapable of transcriptionally activating its target
genes.
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